CN116272708A - 一种量子点-抗体复合物微球及其制备方法、应用 - Google Patents
一种量子点-抗体复合物微球及其制备方法、应用 Download PDFInfo
- Publication number
- CN116272708A CN116272708A CN202310251435.2A CN202310251435A CN116272708A CN 116272708 A CN116272708 A CN 116272708A CN 202310251435 A CN202310251435 A CN 202310251435A CN 116272708 A CN116272708 A CN 116272708A
- Authority
- CN
- China
- Prior art keywords
- quantum dot
- solution
- antibody complex
- antibody
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 49
- 239000002131 composite material Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000000243 solution Substances 0.000 claims abstract description 101
- 239000002096 quantum dot Substances 0.000 claims abstract description 38
- 229940045513 CTLA4 antagonist Drugs 0.000 claims abstract description 34
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims abstract description 26
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 25
- 238000003756 stirring Methods 0.000 claims abstract description 24
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000008055 phosphate buffer solution Substances 0.000 claims abstract description 19
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 17
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 17
- 235000021119 whey protein Nutrition 0.000 claims abstract description 17
- 239000012460 protein solution Substances 0.000 claims abstract description 15
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 239000002244 precipitate Substances 0.000 claims abstract description 6
- 239000004094 surface-active agent Substances 0.000 claims abstract description 5
- 238000002604 ultrasonography Methods 0.000 claims abstract description 5
- 238000005119 centrifugation Methods 0.000 claims abstract description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims abstract 5
- PLMFYJJFUUUCRZ-UHFFFAOYSA-M decyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)C PLMFYJJFUUUCRZ-UHFFFAOYSA-M 0.000 claims abstract 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 14
- 229940098773 bovine serum albumin Drugs 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- -1 alkyl glucoside Chemical class 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- 229930182478 glucoside Natural products 0.000 claims description 8
- 239000008363 phosphate buffer Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 230000035484 reaction time Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- ROIZVGRATDGDLC-UHFFFAOYSA-L dodecyl(trimethyl)azanium dibromide Chemical compound [Br-].[Br-].CCCCCCCCCCCC[N+](C)(C)C.CCCCCCCCCCCC[N+](C)(C)C ROIZVGRATDGDLC-UHFFFAOYSA-L 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 108010045634 B7 Antigens Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000012177 negative regulation of immune response Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明提出了一种量子点‑抗体复合物微球及其制备方法、应用,包括:取量子点溶液,加入EDC溶液,涡旋混匀,加入NHS溶液和纳米抗体Nb90溶液,轻轻搅拌,培养后离心,加入磷酸盐缓冲液溶液进行重悬,加入水解乳清蛋白溶液,反应后,加入乙醇胺,终止反应,离心,收集沉淀物,加入磷酸盐缓冲液溶液进行重悬,得的修饰量子点‑抗体复合物溶液;取DTAB加入修饰量子点‑抗体复合物溶液,超声,加入表面活性剂,搅拌反应后,加入乳清蛋白溶液,搅拌,得量子点‑抗体复合物微球溶液。本发明选用CTLA‑4特异性抗体与量子点结合,得量子点‑抗体复合物微球,CTLA‑4特异性抗体可有效结合CTLA‑4+T细胞,量子点则提供强的荧光信号,能够用于检测CTLA‑4+T细胞。
Description
技术领域
本发明涉及抗原检测领域,特别涉及一种量子点-抗体复合物微球及其制备方法、应用。
背景技术
细胞毒T淋巴细胞相关抗原4(cytotoxic T lymphocyte-associated antigen-4,CTLA-4)又名CD152,是一种白细胞分化抗原,是T细胞上的一种跨膜受体,与CD28共同享有B7分子配体,而CTLA-4与B7分子结合后诱导T细胞无反应性,参与免疫反应的负调节。
目前,多种方法用于检测CTLA-4+ T细胞,其中荧光偶联单克隆抗体(单克隆抗体)是最常用的方法。由于CTLA-4+ T细胞亚群在外周血和肿瘤组织中的比例较低,且易受到肿瘤微环境的干扰,导致采用单克隆抗体检测时难度增加,且费用昂贵。因此,迫切需要一种更简单、更敏感的检测方法来监测CTLA-4+T细胞亚群。纳米体(Nbs)是一种特殊类型的单结构域抗体,由不同区域的重链抗体组成,存在于骆驼的血液中。与传统抗体相比,Nbs具有高特异性、理化稳定性高、缺乏免疫原性、产量高、成本低等优点,适合于癌症的免疫靶向诊断和治疗。采用CTLA-4特异性抗体,并与CTLA 4+ T细胞有效结合,能够有效提高对CTLA4+ T细胞检测的特异性和敏感性。
发明内容
鉴于此,本发明的目的在于提出一种量子点-抗体复合物微球及其制备方法、应用,解决上述问题。
本发明的技术方案是这样实现的:
一种量子点-抗体复合物微球的制备方法,包括如下步骤:
S1配制量子点溶液:在磷酸盐缓冲液中加入量子点,振荡,静置,得量子点溶液;
S2制备量子点-抗体复合物:采用磷酸盐缓冲液溶液溶解纳米抗体Nb90,得纳米抗体Nb90溶液;
取步骤S1的量子点溶液,加入EDC溶液,涡旋混匀,加入NHS溶液和纳米抗体Nb90溶液,轻轻搅拌,培养;培养后离心,收集共轭量子点-抗体复合物,加入含有牛血清白蛋白的磷酸盐缓冲液溶液进行重悬,得量子点-抗体复合物溶液;
在量子点-抗体复合物溶液中加入水解乳清蛋白溶液,于36-38℃反应后,加入乙醇胺,于36-38℃终止反应,离心,收集沉淀物,加入含有牛血清白蛋白的磷酸盐缓冲液溶液进行重悬,得的修饰量子点-抗体复合物溶液;
S3制备量子点-抗体复合物微球溶液:取DTAB加入水,边搅拌边加入步骤S2的修饰量子点-抗体复合物溶液,超声,加入表面活性剂,搅拌反应后,加入乳清蛋白溶液,搅拌,得量子点-抗体复合物微球溶液。
进一步说明,步骤S2中,所述纳米抗体Nb90溶液的质量浓度为0.8-1.5mg/mL。
进一步说明,步骤S2中,所述量子点溶液、DEC溶液、NHS溶液和纳米抗体Nb90溶液的体积比为4-4.5:10-12:10-12:25-27,EDC溶液的浓度为1-1.4mM,NHS溶液的浓度为1-1.4mM;所述培养1-1.5h,所述离心的条件为:10000-12000r/min离心20-30min。
进一步说明,步骤S2中,所述量子点-抗体复合物溶液的质量浓度为8-12mg/mL,所述修饰量子点-抗体复合物溶液的质量浓度为4-6mg/mL。
进一步说明,步骤S2中,所述量子点-抗体复合物溶液、水解乳清蛋白溶液和乙醇胺的体积比为25-27:1-1.2:3-3.5,所述36-38℃反应30-40min,所述36-38℃终止反应30-40min。
进一步说明,步骤S3中,所述DTAB、水和修饰量子点-抗体复合物溶液的料液质量体积比为15-17mg:20-22mL:1.5-2mL。
进一步说明,步骤S3中,所述超声的条件为:超声温度为4-5℃,超声功率为300-400W,超声时间为30-40min;所述搅拌反应的时间为9-11h。
进一步说明,步骤S3中,所述表面活性剂为烷基葡糖苷,烷基葡糖苷的加入量为体系的2.5-4wt%。
进一步说明,本发明提供一种量子点-抗体复合物微球的制备方法制备得到的量子点-抗体复合物微球。
进一步说明,本发明提供一种量子点-抗体复合物微球在提高与CTLA-4+T细胞的结合率中的应用。
与现有技术相比,本发明的有益效果为:
本发明选用CTLA-4特异性抗体与量子点结合,提供一种新的量子点-抗体复合物微球,CTLA-4特异性抗体可有效结合CTLA-4+ T细胞,量子点则提供强的荧光信号,采用量子点-抗体复合物微球能够用于检测CTLA-4+ T细胞。
其中,本发明通过水解乳清蛋白溶液和乙醇胺制成的修饰量子点-抗体复合物,结合DTAB、烷基葡糖苷和乳清蛋白制成的量子点-抗体复合物微球,在PHA刺激的细胞中,量子点-抗体复合物微球与CTLA-4+ T细胞具有较强的特异性结合,在肿瘤浸润的T细胞中,量子点-抗体复合物微球检测到的阳性细胞数量高于抗CTLA-4单抗,这些结果表明,量子点-抗体复合物微球的检测效率明显高于抗CTLA-4单抗,提高检测CTLA-4+ T细胞的特异性和荧光强度。
本发明获得的量子点-抗体复合物微球对细胞无毒性,本发明提供的特异性抗体与量子点结合的方法,也可用于其他靶点的特异性抗来检测其他生物靶点,方法简单,效果明显,优于单克隆抗体的检测。
具体实施方式
为了更好理解本发明技术内容,下面提供具体实施例,对本发明做进一步的说明。
本发明实施例所用的实验方法如无特殊说明,均为常规方法。
本发明实施例所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
实施例1
S1配制量子点溶液:在磷酸盐缓冲液中加入量子点,振荡4min,静置4h,得量子点溶液;
S2制备量子点-抗体复合物:采用磷酸盐缓冲液溶液溶解纳米抗体Nb90,得到质量浓度为1mg/mL的纳米抗体Nb90溶液;
取80μL量子点溶液,加入200μL EDC(1-乙基-3[3-二甲基氨基丙基]碳二亚胺盐酸盐Thermo Scientific Pierce,简称EDC)溶液(1.2mM),涡旋混匀10min,加入200μL NHS溶液(N-羟基琥珀酰亚胺N-Hydroxysuccinimide,简称NHS)(1.2mM)和500μL纳米抗体Nb90溶液(1mg/mL),轻轻搅拌,培养1h;10000r/min离心20min,收集共轭量子点-抗体复合物,加入含有1%(m/v)牛血清白蛋白的磷酸盐缓冲液溶液进行重悬,得质量浓度10mg/mL的量子点-抗体复合物溶液;
在50μL量子点-抗体复合物溶液中20μL加入质量浓度8%的水解乳清蛋白溶液,于37℃反应30min后,加入6μL的乙醇胺,于37℃终止反应30min,10000r/min离心20min,收集沉淀物,加入含有1%(m/v)牛血清白蛋白的磷酸盐缓冲液溶液进行重悬,得质量浓度5mg/mL的修饰量子点-抗体复合物溶液;
S3制备量子点-抗体复合物微球溶液:取15mg DTAB(十二烷基三甲基溴化铵Dodecyltrimethylammonium bromide,简称DTAB)加入22mL水,边搅拌边加入2mL质量浓度5mg/mL的修饰量子点-抗体复合物溶液,4℃、400W超声30min,加入3wt%烷基葡糖苷,搅拌反应10h后,加入质量浓度8%的乳清蛋白溶液,搅拌40min,得量子点-抗体复合物微球溶液。
实施例2
S1配制量子点溶液:在磷酸盐缓冲液中加入量子点,振荡4min,静置4h,得量子点溶液;
S2制备量子点-抗体复合物:采用磷酸盐缓冲液溶液溶解纳米抗体Nb90,得到质量浓度为1.5mg/mL的纳米抗体Nb90溶液;
取90μL量子点溶液,加入240μL EDC(1-乙基-3[3-二甲基氨基丙基]碳二亚胺盐酸盐Thermo Scientific Pierce,简称EDC)溶液(1.2mM),涡旋混匀10min,加入240μL NHS溶液(N-羟基琥珀酰亚胺N-Hydroxysuccinimide,简称NHS)(1.2mM)和540μL纳米抗体Nb90溶液(1.5mg/mL),轻轻搅拌,培养1.5h;10000r/min离心30min,收集共轭量子点-抗体复合物,加入含有1%(m/v)牛血清白蛋白的磷酸盐缓冲液溶液进行重悬,得质量浓度12mg/mL的量子点-抗体复合物溶液;
在50μL量子点-抗体复合物溶液中20μL加入质量浓度8%的水解乳清蛋白溶液,于37℃反应40min后,加入6μL的乙醇胺,于37℃终止反应40min,10000r/min离心20min,收集沉淀物,加入含有1%(m/v)牛血清白蛋白的磷酸盐缓冲液溶液进行重悬,得质量浓度6mg/mL的修饰量子点-抗体复合物溶液;S3制备量子点-抗体复合物微球溶液:取15mg DTAB(十二烷基三甲基溴化铵Dodecyltrimethylammonium bromide,简称DTAB)加入22mL水,边搅拌边加入2mL质量浓度5mg/mL的修饰量子点-抗体复合物溶液,4℃、300W超声40min,加入4wt%烷基葡糖苷,搅拌反应10h后,加入质量浓度8%的乳清蛋白溶液,搅拌40min,得量子点-抗体复合物微球溶液。
对比例1
S1配制量子点溶液:在磷酸盐缓冲液中加入量子点,振荡4min,静置4h,得量子点溶液;
S2制备量子点-抗体复合物:采用磷酸盐缓冲液溶液溶解纳米抗体Nb90,得到质量浓度为1mg/mL的纳米抗体Nb90溶液;
取80μL量子点溶液,加入200μL EDC(1-乙基-3[3-二甲基氨基丙基]碳二亚胺盐酸盐Thermo Scientific Pierce,简称EDC)溶液(1.2mM),涡旋混匀10min,加入200μL NHS溶液(N-羟基琥珀酰亚胺N-Hydroxysuccinimide,简称NHS)(1.2mM)和500μL纳米抗体Nb90溶液(1mg/mL),轻轻搅拌,培养1h;10000r/min离心20min,收集共轭量子点-抗体复合物,加入含有1%(m/v)牛血清白蛋白的磷酸盐缓冲液溶液进行重悬,得质量浓度10mg/mL的量子点-抗体复合物溶液。
对比例2
S1配制量子点溶液:在磷酸盐缓冲液中加入量子点,振荡4min,静置4h,得量子点溶液;
S2制备量子点-抗体复合物:采用磷酸盐缓冲液溶液溶解纳米抗体Nb90,得到质量浓度为1mg/mL的纳米抗体Nb90溶液;
取80μL量子点溶液,加入200μL EDC(1-乙基-3[3-二甲基氨基丙基]碳二亚胺盐酸盐Thermo Scientific Pierce,简称EDC)溶液(1.2mM),涡旋混匀10min,加入200μL NHS溶液(N-羟基琥珀酰亚胺N-Hydroxysuccinimide,简称NHS)(1.2mM)和500μL纳米抗体Nb90溶液(1mg/mL),轻轻搅拌,培养1h;10000r/min离心20min,收集共轭量子点-抗体复合物,加入含有1%(m/v)牛血清白蛋白的磷酸盐缓冲液溶液进行重悬,得质量浓度10mg/mL的量子点-抗体复合物溶液;
在50μL量子点-抗体复合物溶液中20μL加入质量浓度8%的水解乳清蛋白溶液,于37℃反应30min后,加入6μL的乙醇胺,于37℃终止反应30min,10000r/min离心20min,收集沉淀物,加入含有1%(m/v)牛血清白蛋白的磷酸盐缓冲液溶液进行重悬,得质量浓度5mg/mL的修饰量子点-抗体复合物溶液。
实施例3
分离外周血单个核细胞,在含有10%的胎牛血清的RPMI 1640培养基中,于37℃培养2h后,去除贴壁细胞,用尼龙毛分离T细胞,得T细胞;取质量浓度10μg/mL PHA,(聚羟基脂肪酸Polyhydroxyalkanoates,简称PHA),加入T细胞(细胞密度为1×106个),加入2% BSA(牛血清白蛋白),于24℃搅拌孵化30min,以避免非特异性结合,采用300μL磷酸盐缓冲液重悬T细胞,至细胞密度为4×105个,加入上述实施例的量子点-抗体复合物微球溶液,在RPMI1640培养基中,于4℃培养30min后,冲洗,300μL磷酸盐缓冲液重悬刺激T细胞,对照组给予等效剂量的抗CTLA-4单抗和量子点,采用PBS缓冲液洗涤3次,然后用质量浓度4%聚甲醛室温固定15min,PBS缓冲液洗涤后,在4℃结合缓冲液中孵育50min,PBS缓冲液洗涤3次,重悬细胞,采用流式细胞术检测结合率,结果如下表1。
表1
项目 | 实施例1 | 量子点 | 抗CTLA-4单抗 | 对比例1 | 对比例2 |
结合率/% | 45.8 | 0.25 | 30.7 | 34.9 | 38.3 |
由上表1可知,量子点-抗体复合物微球和抗CTLA-4单抗特异性结合到CTLA-4+ T细胞。在Pha刺激的细胞中,与抗CTLA-4单抗相比,量子点-抗体复合物微球与CTLA-4+ T细胞的结合率更高,而量子点的结合率则最小,表明量子点-抗体复合物微球可用于高效地检测CTLA-4+ T细胞。
与对比例1和2相比,本发明通过水解乳清蛋白溶液和乙醇胺制成的修饰量子点-抗体复合物,结合DTAB、烷基葡糖苷和乳清蛋白制成的量子点-抗体复合物微球,可更有效提高与CTLA-4+ T细胞的结合效率。
实施例4
将肿瘤组织以及邻近粘膜浸泡在最佳切割温度的化合物中,加工成冷冻切片(-20℃)。采用量子点-抗体复合物微球溶液、抗CTLA-4单抗和量子点分别孵育后进行免疫荧光染色。将样品组织切割后,加入EDTA抗原修复缓冲液(pH8.0)浸泡5min,缓慢加热至99℃并持续10min进行抗原修复,将切片放入PBS冲洗缓冲液中浸泡清洗两次,每次5min,加入胶原酶II进行消化,使用抗人CD3单克隆抗体免疫磁珠试剂盒,通过流式细胞术进行分析,检测CD3和CTLA-4表达的特异性抗体(抗人CD3单抗、量子点-抗体复合物微球、抗CTLA-4单抗和量子点的浓度为100nM,4℃孵育30min),结果如下表2。
表2
项目 | 实施例1 | 量子点 | 抗CTLA-4单抗 | 对比例1 | 对比例2 |
肿瘤 | 16.2 | 0.30 | 12.1 | 12.5 | 14.2 |
邻近粘膜 | 5.7 | 0.22 | 3.9 | 4.2 | 4.5 |
由上表2可知,对肿瘤组织和邻近粘膜进行免疫荧光染色,研究量子点-抗体复合物微球或抗CTLA-4单抗在肿瘤组织中浸润的CTLA-4+ T细胞的荧光信号明显高于邻近粘膜。量子点-抗体复合物微球检测到的阳性细胞数量高于抗CTLA-4单抗。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种量子点-抗体复合物微球的制备方法,其特征在于,包括如下步骤:
S1配制量子点溶液:在磷酸盐缓冲液中加入量子点,振荡,静置,得量子点溶液;
S2制备量子点-抗体复合物:采用磷酸盐缓冲液溶液溶解纳米抗体Nb90,得纳米抗体Nb90溶液;
取步骤S1的量子点溶液,加入EDC溶液,涡旋混匀,加入NHS溶液和纳米抗体Nb90溶液,轻轻搅拌,培养;培养后离心,收集共轭量子点-抗体复合物,加入含有牛血清白蛋白的磷酸盐缓冲液溶液进行重悬,得量子点-抗体复合物溶液;
在量子点-抗体复合物溶液中加入水解乳清蛋白溶液,于36-38℃反应后,加入乙醇胺,于36-38℃终止反应,离心,收集沉淀物,加入含有牛血清白蛋白的磷酸盐缓冲液溶液进行重悬,得的修饰量子点-抗体复合物溶液;
S3制备量子点-抗体复合物微球溶液:取DTAB加入水,边搅拌边加入步骤S2的修饰量子点-抗体复合物溶液,超声,加入表面活性剂,搅拌反应后,加入乳清蛋白溶液,搅拌,得量子点-抗体复合物微球溶液。
2.根据权利要求1的一种量子点-抗体复合物微球的制备方法,其特征在于,步骤S2中,所述纳米抗体Nb90溶液的质量浓度为0.8-1.5mg/mL。
3.根据权利要求1的一种量子点-抗体复合物微球的制备方法,其特征在于,步骤S2中,所述量子点溶液、DEC溶液、NHS溶液和纳米抗体Nb90溶液的体积比为4-4.5:10-12:10-12:25-27,EDC溶液的浓度为1-1.4mM,NHS溶液的浓度为1-1.4mM;所述培养1-1.5h,所述离心的条件为:10000-12000r/min离心20-30min。
4.根据权利要求1的一种量子点-抗体复合物微球的制备方法,其特征在于,步骤S2中,所述量子点-抗体复合物溶液的质量浓度为8-12mg/mL,所述修饰量子点-抗体复合物溶液的质量浓度为4-6mg/mL。
5.根据权利要求1的一种量子点-抗体复合物微球的制备方法,其特征在于,步骤S2中,所述量子点-抗体复合物溶液、水解乳清蛋白溶液和乙醇胺的体积比为25-27:1-1.2:3-3.5,所述36-38℃反应30-40min,所述36-38℃终止反应30-40min。
6.根据权利要求1的一种量子点-抗体复合物微球的制备方法,其特征在于,步骤S3中,所述DTAB、水和修饰量子点-抗体复合物溶液的料液质量体积比为15-17mg:20-22mL:1.5-2mL。
7.根据权利要求1的一种量子点-抗体复合物微球的制备方法,其特征在于,步骤S3中,所述超声的条件为:超声温度为4-5℃,超声功率为300-400W,超声时间为30-40min;所述搅拌反应的时间为9-11h。
8.根据权利要求1的一种量子点-抗体复合物微球的制备方法,其特征在于,步骤S3中,所述表面活性剂为烷基葡糖苷,烷基葡糖苷的加入量为体系的2.5-4wt%。
9.根据权利要求1~8任意一项的一种量子点-抗体复合物微球的制备方法制备得到的量子点-抗体复合物微球。
10.根据权利要求9的一种量子点-抗体复合物微球的应用,其特征在于,所述量子点-抗体复合物微球在提高与CTLA-4+T细胞的结合率中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310251435.2A CN116272708B (zh) | 2023-03-16 | 2023-03-16 | 一种量子点-抗体复合物微球及其制备方法、应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310251435.2A CN116272708B (zh) | 2023-03-16 | 2023-03-16 | 一种量子点-抗体复合物微球及其制备方法、应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116272708A true CN116272708A (zh) | 2023-06-23 |
CN116272708B CN116272708B (zh) | 2023-11-14 |
Family
ID=86816317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310251435.2A Active CN116272708B (zh) | 2023-03-16 | 2023-03-16 | 一种量子点-抗体复合物微球及其制备方法、应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116272708B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117147830A (zh) * | 2023-10-26 | 2023-12-01 | 德州国科医疗科技有限公司 | 一种特异性真菌d-葡聚糖检测荧光染色液 |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09304380A (ja) * | 1996-05-10 | 1997-11-28 | Asahi Chem Ind Co Ltd | 抗原の取得方法および使用方法 |
US20060024379A1 (en) * | 2004-05-12 | 2006-02-02 | Larry Brown | Protein microspheres having injectable properties at high concentrations |
CN103109001A (zh) * | 2010-07-05 | 2013-05-15 | 阿茨拉实验室有限公司 | 制造诊断组合物的方法以及由其制得的组合物 |
WO2013102144A2 (en) * | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
CN103370072A (zh) * | 2010-12-15 | 2013-10-23 | 巴克斯特国际公司 | 使用改进的溶剂-清洁剂方法进行病毒灭活 |
CN104448169A (zh) * | 2014-12-16 | 2015-03-25 | 湖南科技大学 | 一种光/温度双响应的共聚物修饰的荧光碳纳米颗粒 |
CN105452466A (zh) * | 2012-10-23 | 2016-03-30 | 卡里斯生命科学瑞士控股有限责任公司 | 适体及其用途 |
CN109929549A (zh) * | 2017-12-15 | 2019-06-25 | Tcl集团股份有限公司 | 一种量子点复合材料及其制备方法 |
WO2019246455A1 (en) * | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
CN112157271A (zh) * | 2020-10-10 | 2021-01-01 | 海南医学院 | 一种藿香蓟提取液制备纳米银胶的方法及应用 |
WO2021097301A1 (en) * | 2019-11-15 | 2021-05-20 | Christopher Gordon Atwood | Compositions and methods based on diffusion of fluorophores |
CN113045662A (zh) * | 2021-05-31 | 2021-06-29 | 西宝生物科技(上海)股份有限公司 | 一种特异性识别pd-l1的纳米抗体及其应用 |
CN113884676A (zh) * | 2021-09-30 | 2022-01-04 | 杭州联科生物技术股份有限公司 | 一种通过将荧光微球偶联抗体检测目的蛋白的方法 |
CN114306191A (zh) * | 2022-01-28 | 2022-04-12 | 海南医学院 | 一种天然植物防晒霜及其制备方法 |
CN114845721A (zh) * | 2019-10-30 | 2022-08-02 | 奥德纳米有限公司 | 用于药物诱导的耳毒性的耳用制剂 |
WO2022211014A1 (ja) * | 2021-03-31 | 2022-10-06 | 株式会社カネカ | 凝集性タンパク質の測定方法及び凝集可視化方法、並びにこれらの方法に使用するためのキット |
CN115607677A (zh) * | 2022-05-06 | 2023-01-17 | 太阳雨林(北京)生物医药有限公司 | 预防、阻止或治疗微生物感染的复合物及其制备和应用 |
US20230017661A1 (en) * | 2019-12-13 | 2023-01-19 | Veri Nano Inc. | Compositions and modular nano- and microparticles for the delivery of various agents and use thereof |
-
2023
- 2023-03-16 CN CN202310251435.2A patent/CN116272708B/zh active Active
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09304380A (ja) * | 1996-05-10 | 1997-11-28 | Asahi Chem Ind Co Ltd | 抗原の取得方法および使用方法 |
US20060024379A1 (en) * | 2004-05-12 | 2006-02-02 | Larry Brown | Protein microspheres having injectable properties at high concentrations |
CN103109001A (zh) * | 2010-07-05 | 2013-05-15 | 阿茨拉实验室有限公司 | 制造诊断组合物的方法以及由其制得的组合物 |
CN103370072A (zh) * | 2010-12-15 | 2013-10-23 | 巴克斯特国际公司 | 使用改进的溶剂-清洁剂方法进行病毒灭活 |
WO2013102144A2 (en) * | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
CN105452466A (zh) * | 2012-10-23 | 2016-03-30 | 卡里斯生命科学瑞士控股有限责任公司 | 适体及其用途 |
CN104448169A (zh) * | 2014-12-16 | 2015-03-25 | 湖南科技大学 | 一种光/温度双响应的共聚物修饰的荧光碳纳米颗粒 |
CN109929549A (zh) * | 2017-12-15 | 2019-06-25 | Tcl集团股份有限公司 | 一种量子点复合材料及其制备方法 |
WO2019246455A1 (en) * | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
CN114845721A (zh) * | 2019-10-30 | 2022-08-02 | 奥德纳米有限公司 | 用于药物诱导的耳毒性的耳用制剂 |
WO2021097301A1 (en) * | 2019-11-15 | 2021-05-20 | Christopher Gordon Atwood | Compositions and methods based on diffusion of fluorophores |
US20230017661A1 (en) * | 2019-12-13 | 2023-01-19 | Veri Nano Inc. | Compositions and modular nano- and microparticles for the delivery of various agents and use thereof |
CN112157271A (zh) * | 2020-10-10 | 2021-01-01 | 海南医学院 | 一种藿香蓟提取液制备纳米银胶的方法及应用 |
WO2022211014A1 (ja) * | 2021-03-31 | 2022-10-06 | 株式会社カネカ | 凝集性タンパク質の測定方法及び凝集可視化方法、並びにこれらの方法に使用するためのキット |
CN113045662A (zh) * | 2021-05-31 | 2021-06-29 | 西宝生物科技(上海)股份有限公司 | 一种特异性识别pd-l1的纳米抗体及其应用 |
CN113884676A (zh) * | 2021-09-30 | 2022-01-04 | 杭州联科生物技术股份有限公司 | 一种通过将荧光微球偶联抗体检测目的蛋白的方法 |
CN114306191A (zh) * | 2022-01-28 | 2022-04-12 | 海南医学院 | 一种天然植物防晒霜及其制备方法 |
CN115607677A (zh) * | 2022-05-06 | 2023-01-17 | 太阳雨林(北京)生物医药有限公司 | 预防、阻止或治疗微生物感染的复合物及其制备和应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117147830A (zh) * | 2023-10-26 | 2023-12-01 | 德州国科医疗科技有限公司 | 一种特异性真菌d-葡聚糖检测荧光染色液 |
CN117147830B (zh) * | 2023-10-26 | 2024-01-12 | 德州国科医疗科技有限公司 | 一种特异性真菌d-葡聚糖检测荧光染色液 |
Also Published As
Publication number | Publication date |
---|---|
CN116272708B (zh) | 2023-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guerriero et al. | Thrombopoietin is synthesized by bone marrow stromal cells | |
CN116272708B (zh) | 一种量子点-抗体复合物微球及其制备方法、应用 | |
Bouscary et al. | Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes | |
Lipinski et al. | Human trophoblast cell-surface antigens defined by monoclonal antibodies. | |
Alcorn et al. | Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction | |
Budzko et al. | Activation of the alternative complement pathway by lymphoblastoid cell lines derived from patients with Burkitt's lymphoma and infectious mononucleosis | |
Goldstein et al. | Direct membrane immunofluorescence reaction of Burkitt's lymphoma cells in culture | |
US6828109B2 (en) | Methods for detecting an analyte of interest using catalyzed reporter deposition of tyramide | |
JPH03501560A (ja) | 食細胞の細胞表面タンパク質の付着機能領域に特異的なモノクローナル抗体 | |
Krishnaraj et al. | Age-associated alterations in human natural killer cells: 2. Increased frequency of selective NK subsets | |
Jung et al. | Different diuresis-dependent excretions of urinary enzymes: N-acetyl-beta-D-glucosaminidase, alanine aminopeptidase, alkaline phosphatase, and gamma-glutamyltransferase. | |
JP4102840B2 (ja) | フィコビリソーム、誘導体およびその使用 | |
CN103033625A (zh) | 一种人膀胱癌细胞化学发光检测试剂盒及其制备方法 | |
US20240125780A1 (en) | Method for detecting anti-car antibody against humanized cart cells | |
CN108588031B (zh) | 抗人IgM单克隆抗体、其杂交瘤细胞株及应用 | |
CN107328620B (zh) | 用于流式细胞技术的封闭缓冲液及试剂盒 | |
CN111308063B (zh) | 藻红蛋白免疫荧光探针标记方法 | |
Tsutsui et al. | Immunofluorescent study of non-histone protein-DNA complexes in cultured cells and lymphocytes | |
Letvin et al. | Surface antigen changes during B-lymphocyte activation in primates | |
JPH04502363A (ja) | 癌及びその他の疾病の診断としての基底膜成分の検出 | |
JPS62500868A (ja) | モノクロ−ナル抗体およびその用途 | |
US20020076732A1 (en) | Methods for detecting an analyte of interest using catalyzed reporter deposition of tyramide | |
Rousseau-Merck et al. | Tumor cell line characterization of a malignant histiocytosis transplanted into nude mice | |
Keizer et al. | Sensitive and quantitative determination of monocyte adherence | |
Santiago‐Schwarz et al. | Functional Analysis of Monocyte‐Macrophages Derived From Nonadherent Cord Blood Progenitor Cells: Correlation With the Ontogeny of Cell Surface Proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240222 Address after: Shop 01, 2nd Floor, Building C, No. 46 Chengxi Road, Longhua District, Haikou City, Hainan Province, 571101 Patentee after: Hainan Junxiong Construction Group Co.,Ltd. Country or region after: China Address before: 571199 Xueyuan Road, Longhua District, Haikou, Hainan Province, No. 3 Patentee before: HAINAN MEDICAL College Country or region before: China |